Sorafenib: a clinical and pharmacologic review.

Abstract:

IMPORTANCE OF THE FIELD:Sorafenib is an oral receptor tyrosine kinase inhibitor that inhibits Raf serine/threonine kinases and receptor tyrosine kinases (vascular endothelial growth factor receptors 1, 2, 3 and platelet-derived growth factor-beta, Flt-3 and c-kit) that are implicated in tumorigenesis and tumor progression. Sorafenib is approved for the treatment of advanced inoperable hepatocellular cancer and advanced renal cell cancer. AREAS COVERED IN THIS REVIEW:The findings from the major Phase III studies that led to FDA approval of this drug for the above indications are reviewed. Key aspects of sorafenib pharmacology, dosing in the presence of organ dysfunction, toxicities and weaknesses of the research done so far are summarized. WHAT WILL THE READER GAIN:The reader will have the knowledge of the major studies that form the basis of the clinical use of sorafenib, information on the upcoming Phase III trials that could lead to changes in clinical practice and some insights on aspects of the drugs' mechanism of action and toxicity that still remain unclear. TAKE HOME MESSAGE:Sorafenib is a well-tolerated oral antiangiogenic agent approved for treatment of two angiogenesis-driven cancers. Studies to broaden the clinical indications and increase understanding of the clinical and laboratory biomarkers of response are needed.

authors

Iyer R,Fetterly G,Lugade A,Thanavala Y

doi

10.1517/14656566.2010.496453

subject

Has Abstract

pub_date

2010-08-01 00:00:00

pages

1943-55

issue

11

eissn

1465-6566

issn

1744-7666

journal_volume

11

pub_type

杂志文章,评审
  • Emerging antiretroviral drugs.

    abstract:INTRODUCTION:The potency, tolerability and convenience of antiretroviral agents have all significantly improved over the past years, making lifelong HIV therapy easier. However, several specific needs are still unmet, including low daily pill burden, friendly metabolic profile, lack of (or few) drug interactions and hi...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2014.863277

    authors: Fernández-Montero JV,Vispo E,Soriano V

    更新日期:2014-02-01 00:00:00

  • Evaluation of injection force of three insulin delivery pens.

    abstract:OBJECTIVE:Reduced injection force is among the modifications to the Next Generation FlexPen (NGFP). This force was compared with two other prefilled pens: SoloStar (SS) and KwikPen (KP). RESEARCH DESIGN/METHODS:The injection force of the pens was measured, with either a BD Micro-Fine 31G thin-wall needle, or a NovoFin...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章

    doi:10.1517/14656560903018929

    authors: Asakura T,Seino H,Kageyama M,Yohkoh N

    更新日期:2009-06-01 00:00:00

  • Pharmacotherapy for the treatment of obstructive hypertrophic cardiomyopathy.

    abstract::Introduction: Hypertrophic cardiomyopathy (HCM) is one of the most common genetic heart diseases and represents a leading cause of sudden cardiac death as well as a prevalent cause of heart failure and stroke. HCM is characterized by a very complex pathophysiology, consisting of heterogeneous clinical manifestations a...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1080/14656566.2019.1702023

    authors: Spoladore R,Fragasso G,Pannone L,Slavich M,Margonato A

    更新日期:2020-02-01 00:00:00

  • Targeting the Janus kinases in rheumatoid arthritis: focus on tofacitinib.

    abstract:INTRODUCTION:Treatment of rheumatoid arthritis (RA) has markedly advanced by the advent of biologic disease-modifying antirheumatic drugs (DMARDs). However, they require special storage and transportation and remission is observed in ∼ 30%. Tofacitinib inhibits the nonreceptor tyrosine kinase family Janus kinase (JAK),...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2014.854771

    authors: Yamaoka K,Tanaka Y

    更新日期:2014-01-01 00:00:00

  • Fixed combinations of dorzolamide-timolol and brimonidine-timolol in the management of glaucoma.

    abstract:IMPORTANCE OF THE FIELD:The emergence of fixed-combination drugs for the treatment of glaucoma has, to some extent, changed the medical management of glaucoma. The potential benefits of these drugs include a reduction in the total number of drops and preservatives instilled per day and improved patient comfort factors,...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656561003667540

    authors: Razeghinejad MR,Sawchyn AK,Katz LJ

    更新日期:2010-04-01 00:00:00

  • Neuroprotection and thrombolysis: combination therapy in acute ischaemic stroke.

    abstract::The administration of oral aspirin within 48 h and tissue plasminogen activator within 3 h of ischaemic stroke onset remain the only treatments that have been shown to have clinical benefit. There has been much excitement about neuroprotection over the last two decades, as it may minimise the harmful effects of ischae...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.7.12.1571

    authors: Ly JV,Zavala JA,Donnan GA

    更新日期:2006-08-01 00:00:00

  • Neuraminidase inhibitors as a strategy for influenza treatment: pros, cons and future perspectives.

    abstract::Introduction: Influenza represents a major public health threat worldwide. Implementation of good personal health and hygiene habits, together with vaccination, is the most effective tools to reduce influenza burden both in community and in healthcare setting. However, achieving adequate vaccination rates is challengi...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1080/14656566.2019.1626824

    authors: Bassetti M,Castaldo N,Carnelutti A

    更新日期:2019-10-01 00:00:00

  • The trade-off dilemma in pharmacotherapy of COVID-19: systematic review, meta-analysis, and implications.

    abstract:INTRODUCTION:The coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has infected millions of people worldwide and has contributed to over 650,000 deaths. This review synthesizes the literature on COVID-19 pharmacotherapy to inform practice and policymaking. A...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,meta分析

    doi:10.1080/14656566.2020.1792884

    authors: Khan S,Gionfriddo MR,Cortes-Penfield N,Thunga G,Rashid M

    更新日期:2020-10-01 00:00:00

  • Sorafenib in liver cancer.

    abstract:INTRODUCTION:With growing knowledge of the molecular pathway of carcinogenesis, targeted therapies have become the 'blue ocean' of cancer treatment. sorafenib is an oral multikinase inhibitor that targets Raf/mitogen-activated protein (MAP) kinase/extracellular signal-regulated kinase (ERK) (Raf/MEK/ERK) and several ty...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2012.679930

    authors: Woo HY,Heo J

    更新日期:2012-05-01 00:00:00

  • Drug interactions in the management of HIV infection.

    abstract::The availability of antiretroviral therapy has significantly reduced the morbidity and mortality of HIV infection. In addition, improved treatment of opportunistic infections and comorbidities common to patients with HIV is further prolonging the lives of patients. Improvement in the treatment of HIV has led to a sign...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.6.2.233

    authors: Robertson SM,Penzak SR,Pau AK

    更新日期:2005-02-01 00:00:00

  • An overview of pharmacotherapy for bipolar I disorder.

    abstract:INTRODUCTION:Bipolar I disorder (BD I) is complex with a chronic course that significantly impacts a sufferer's quality of life. As of right now, there are many available treatments that aim to rapidly treat manic or depressive episodes and stabilize mood. The purpose of this report is to provide an up-to-date comprehe...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1080/14656566.2018.1426746

    authors: Morsel AM,Morrens M,Sabbe B

    更新日期:2018-02-01 00:00:00

  • Pharmacotherapies for the treatment of glioblastoma - current evidence and perspectives.

    abstract:INTRODUCTION:Glioblastoma, the most common malignant brain tumor, exhibits a poor prognosis with little therapeutic progress in the last decade. Novel treatment strategies beyond the established standard of care with temozolomide-based radiotherapy are urgently needed. AREAS COVERED:We reviewed the literature on gliob...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1080/14656566.2016.1176146

    authors: Seystahl K,Gramatzki D,Roth P,Weller M

    更新日期:2016-06-01 00:00:00

  • Treatment options for chronic myeloid leukemia.

    abstract:INTRODUCTION:The bcr-abl tyrosine kinase inhibitors (TKIs) are the cornerstone treatment for chronic myeloid leukemia (CML). However, there are many topics related to therapy that remain debated. AREAS COVERED:The aim of this paper is to give the reader a comprehensive review of how to treat CML at diagnosis, how to m...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2012.671296

    authors: Tanaka MF,Kantarjian H,Cortes J,Ohanian M,Jabbour E

    更新日期:2012-04-01 00:00:00

  • Therapeutic options for HIV-associated lymphomas.

    abstract:IMPORTANCE OF THE FIELD:The clinical features and natural history of HIV-associated lymphomas differ greatly from those observed in the general population. The failure to improve outcomes with treatment intensification indicates the need for the introduction of new therapeutic options. AREAS COVERED IN THIS REVIEW:Thi...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2010.502528

    authors: Spina M,Gloghini A,Tirelli U,Carbone A

    更新日期:2010-10-01 00:00:00

  • Fidaxomicin for treatment of clostridium difficile-associated diarrhea and its potential role for prophylaxis.

    abstract:INTRODUCTION:Clostridium difficile has become the most important healthcare-associated infection worldwide within the past decade. This is in part due to the emergence of a highly virulent epidemic strain of C. difficile as well as the relative ineffectiveness of current therapies at producing a sustained response. Fid...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2013.802307

    authors: Hostler CJ,Chen LF

    更新日期:2013-08-01 00:00:00

  • Current and up-and-coming pharmacotherapy for obsessive-compulsive disorder in adults.

    abstract:INTRODUCTION:Only 40-60% of obsessive-compulsive patients respond to first line treatments, such as selective serotonin reuptake inhibitors (SSRIs) and cognitive-behavioral therapy. Several second-line treatments have been investigated in the last two decades, and most of them seem to work, at least in a subset of pati...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1080/14656566.2018.1528230

    authors: Grassi G,Pallanti S

    更新日期:2018-10-01 00:00:00

  • Medical management for neurosurgical related seizures.

    abstract:INTRODUCTION:Seizures or chronic epilepsy are a relatively common occurrence in a neurosurgical setting. However, seizure treatment after neurosurgery has received less attention compared with other causes and only few data are availaible in the literature on management in neurosurgical patients. Areas covered: This pa...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1080/14656566.2017.1373092

    authors: Ambrosi M,Orsini A,Verrotti A,Striano P

    更新日期:2017-10-01 00:00:00

  • Fluticasone propionate: a potent inhaled corticosteroid for the treatment of asthma.

    abstract::Fluticasone propionate (FP) is a potent inhaled corticosteroid (ICS) for the treatment of asthma. It is currently marketed in both the United States (as Flovent) and Europe (as Flixotide). Fluticasone is available in both aerosolised metered dose inhaler (MDI) and dry powder devices, with dosages ranging from 44-500 m...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.1.6.1227

    authors: Staresinic AG,Sorkness CA

    更新日期:2000-09-01 00:00:00

  • Efficacy of indacaterol as a single therapy versus salmeterol/fluticasone therapy in patients with milder chronic obstructive pulmonary disease.

    abstract:INTRODUCTION:In non-exacerbation chronic obstructive pulmonary disease (COPD) with mild lung function impairment, single bronchodilator therapy might be as effective as combined inhaled corticosteroid/bronchodilator therapy, whereas the risk of pneumonia associated with the latter would be practically absent. AREAS CO...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 评论,杂志文章

    doi:10.1517/14656566.2015.1043888

    authors: Ruxandra U,Antoniu SA,Mihaltan F,Boisteanu D

    更新日期:2015-01-01 00:00:00

  • Linagliptin, a dipeptidyl peptidase-4 inhibitor with a unique pharmacological profile, and efficacy in a broad range of patients with type 2 diabetes.

    abstract:INTRODUCTION:Increasing population age, obesity and physical inactivity mean that type 2 diabetes mellitus (T2DM) is increasingly common. Current treatments may be limited by adverse events, drug-drug interactions or contraindication/need for dose adjustment in patients with renal impairment. AREAS COVERED:This paper ...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2012.642863

    authors: Forst T,Pfützner A

    更新日期:2012-01-01 00:00:00

  • The pharmacological management of hairy cell leukemia.

    abstract:INTRODUCTION:Hairy cell leukemia (HCL) is a B-cell lymphoid malignancy that accounts for approximately 2% of all leukemias. Treatment with purine nucleoside analogs (PNA) results in a high response rate and remains the standard of care. Long term follow-up shows that most patients relapse and require retreatment. Newer...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1080/14656566.2020.1754397

    authors: Ramos Perez J,Ravandi-Kashani F

    更新日期:2020-08-01 00:00:00

  • Does antipsychotic combination therapy reduce the risk of hospitalization in schizophrenia?

    abstract:INTRODUCTION:: Despite treatment with antipsychotic medication, approximately 1/3 of individuals with schizophrenia will fail to have an adequate response. To treat these patients, a commonly utilized approach is antipsychotic combination therapy. Antipsychotic combination therapy is controversial with mixed efficacy a...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章

    doi:10.1080/14656566.2020.1847274

    authors: Faden J,Kiryankova-Dalseth N,Barghini R,Citrome L

    更新日期:2020-11-30 00:00:00

  • Insulin analogue therapy in pregnancies complicated by diabetes mellitus.

    abstract::Pregnancies complicated by diabetes mellitus (DM) include pregestational DM and gestational DM, defined as carbohydrate intolerance of variable severity first detected during pregnancy. DM leads to poor pregnancy outcome. The aim of treatment is to control maternal hyperglycaemia and to imitate postprandial insulin re...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.6.5.735

    authors: González C,Santoro S,Salzberg S,Di Girolamo G,Alvariñas J

    更新日期:2005-05-01 00:00:00

  • Advances in chemical pharmacotherapy for managing acute decompensated heart failure.

    abstract:INTRODUCTION:Acute decompensated heart failure (ADHF) contributes largely to the burden of heart failure and is associated with a poorer prognosis. Although numerous clinical trials evaluated the benefit of newer medications for ADHF, most of them were not successful. Areas covered: This review focusses on the updates ...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1080/14656566.2017.1299708

    authors: Yandrapalli S,Tariq S,Aronow WS

    更新日期:2017-04-01 00:00:00

  • The effects of intermittent use of the SGLT-2 inhibitor, dapagliflozin, in overweight patients with type 2 diabetes in Japan: a randomized, crossover, controlled clinical trial.

    abstract:BACKGROUND:This study examined the effects of short-term administration of the sodium glucose cotransporter 2 (SGLT-2) inhibitor, dapagliflozin, on visceral fat area (VFA) in Japanese patients with type 2 diabetes. RESEARCH DESIGN AND METHODS:In this randomized, crossover, controlled clinical trial, overweight patient...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,随机对照试验

    doi:10.1080/14656566.2017.1317748

    authors: Kato K,Suzuki K,Aoki C,Sagara M,Niitani T,Wakamatsu S,Yanagi K,Aso Y

    更新日期:2017-06-01 00:00:00

  • Recommendations for the management of migraine in paediatric patients.

    abstract::Migraine is a common and disabling condition in children and adolescents. The complexity of migraine on a pathogenetic and clinical level results from the interaction between biological, psychological and environmental factors. Appropriate management requires an individually tailored strategy giving due consideration ...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.8.6.731

    authors: Balottin U,Termine C

    更新日期:2007-04-01 00:00:00

  • Which antihypertensive drugs are the most nephroprotective and why?

    abstract:IMPORTANCE OF THE FIELD:Hypertension is a major independent risk factor for kidney disease and for faster renal function loss. Choice of antihypertensive strategies with highest nephroprotective effect is crucial to prevent or reverse progression to end stage renal disease (ESRD). AREAS COVERED IN THIS REVIEW:The pres...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2010.521742

    authors: Cravedi P,Ruggenenti P,Remuzzi G

    更新日期:2010-11-01 00:00:00

  • Olanzapine: a critical review of recent literature.

    abstract::The purpose of this review is to critically review the current literature on olanzapine with an emphasis on emergent themes and key findings in the use of this agent for the treatment of mood disorders and schizophrenia. New information continues to emerge on the impact of olanzapine on schizophrenia and on aspects of...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.6.12.2077

    authors: Buckley PF

    更新日期:2005-10-01 00:00:00

  • From dorzolamide 2%/timolol 0.5% to brinzolamide 1%/timolol 0.5% fixed combination: a 6-month, multicenter, open-label tolerability switch study.

    abstract:PURPOSE:To assess ocular surface status and tolerability after switching glaucoma patients from dorzolamide/timolol to brinzolamide/timolol fixed combination (FC). METHODS:Six-month, multicenter, open-label, prospective study that switched 72 patients from dorzolamide/timolol to brinzolamide/timolol FC. Intraocular pr...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 临床试验,杂志文章,多中心研究

    doi:10.1517/14656566.2011.589384

    authors: Rossi GC,Pasinetti GM,Sandolo F,Bordin M,Bianchi PE

    更新日期:2011-11-01 00:00:00

  • Vaginal ring delivery of hormone replacement therapy--a review.

    abstract::Vaginal ring delivery systems are a highly promising approach to hormone replacement therapy (HRT). The vagina is an excellent route for steroid absorption. Menopausal vaginal rings can be designed to allow very low dose local delivery of oestrogen to the vagina for the large percentage of postmenopausal women experie...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.4.2.201

    authors: Dezarnaulds G,Fraser IS

    更新日期:2003-02-01 00:00:00